Companies › Whitehawk Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HWK-016 MUCIN-16-targeted antibody-drug conjugate | MUC16 | Phase 1 | PROC | Feb 2028 |
| HWK-007 PTK7-directed antibody-drug conjugate | PTK7 | Phase 1 | Endometrial Cancer | Oct 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07470853 | HWK-016 | Phase 1 | PROC | Oncology | Feb 2028 |
| NCT07444814 | HWK-007 | Phase 1 | Endometrial Cancer | Oncology | Oct 2028 |
Cash and short-term investments of $170m on 2026-09-30; operating cash outflow about $76m a year; runway about 27 months at that burn, to Dec 2028
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
IDEAYA Biosciences Day One Biopharmaceuticals Kivu Bioscience CanariaBio Beijing Biotech Regeneron Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.